The epidermal growth factor receptor pathway: A model for targeted therapy

被引：674

作者：

Scaltriti, Maurizio

Baselga, Jose

机构：

[1] Vall Hebron Univ Hosp, Med Oncol Serv, Barcelona 08035, Spain

[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain

[3] Univ Parma, Dipartimento Med Sperimentale, I-43100 Parma, Italy

来源：

CLINICAL CANCER RESEARCH | 2006年 / 12卷 / 18期

关键词：

D O I：

10.1158/1078-0432.CCR-05-1554

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.

引用

页码：5268 / 5272

页数：5

共 59 条

[1] Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation [J].

Anido, Judit ;

Scaltriti, Maurizio ;

Bech Serra, Joan Josep ;

Santiago Josefat, Belen ;

Rojo Todo, Federico ;

Baselga, Jose ;

Arribas, Joaquin .

EMBO JOURNAL, 2006, 25 (13) :3234-3244

[2] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[3] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[4] HIERARCHY OF BINDING-SITES FOR GRB2 AND SHC ON THE EPIDERMAL GROWTH-FACTOR RECEPTOR [J].

BATZER, AG ;

ROTIN, D ;

URENA, JM ;

SKOLNIK, EY ;

SCHLESSINGER, J .

MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (08) :5192-5201

[5] Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

[6] Stat proteins and oncogenesis [J].

Bromberg, J .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1139-1142

[7] An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors [J].

Burgess, AW ;

Cho, HS ;

Eigenbrot, C ;

Ferguson, KM ;

Garrett, TPJ ;

Leahy, DJ ;

Lemmon, MA ;

Sliwkowski, MX ;

Ward, CW ;

Yokoyama, S .

MOLECULAR CELL, 2003, 12 (03) :541-552

[8] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[9]

CARPENTER CL, 1993, J BIOL CHEM, V268, P9478

[10] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

← 1 2 3 4 5 6 →